Who are Control - UFH's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Heparin 50U/ml.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/control-ufh.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Control - UFH — Competitive Intelligence Brief

Control - UFH (Control - UFH) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticoagulant (unfractionated heparin). Area: Cardiovascular.

phase 3 Anticoagulant (unfractionated heparin) Antithrombin III (enhancer); Factors IIa, Xa, and other serine proteases Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Control - UFH (Control - UFH) — GlaxoSmithKline. Unfractionated heparin (UFH) is an anticoagulant that inhibits multiple clotting factors to prevent blood clot formation.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Control - UFH TARGET	Control - UFH	GlaxoSmithKline	phase 3	Anticoagulant (unfractionated heparin)	Antithrombin III (enhancer); Factors IIa, Xa, and other serine proteases
Heparin 50U/ml	Heparin 50U/ml	University of Florence	marketed	Anticoagulant (unfractionated heparin)	Antithrombin III (indirect mechanism); Thrombin and Factor Xa (downstream targets)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticoagulant (unfractionated heparin) class)

GlaxoSmithKline · 1 drug in this class
University of Florence · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Control - UFH — Competitive Intelligence Brief. https://druglandscape.com/ci/control-ufh. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab